Titre:
  • A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
Auteur:Mayer, Erica L; Baurain, Jean-Francois; Sparano, Joseph; Strauss, Lewis; Campone, Mario; Fumoleau, Pierre; Rugo, Hope; Awada, Ahmad; Sy, Oumar; Llombart-Cussac, Antonio
Informations sur la publication:Clinical cancer research, 17, 21, page (6897-6904)
Statut de publication:Publié, 2011-11
Sujet CREF:Cancérologie
MeSH keywords:Administration, Oral
Adult
Aged
Breast Neoplasms -- drug therapy -- metabolism
Female
Humans
Middle Aged
Protein Kinase Inhibitors -- adverse effects -- therapeutic use
Pyrimidines -- adverse effects -- therapeutic use
Receptor, erbB-2 -- biosynthesis
Receptors, Estrogen -- biosynthesis
Receptors, Progesterone -- biosynthesis
Thiazoles -- adverse effects -- therapeutic use
src-Family Kinases -- antagonists & inhibitors -- metabolism
Note générale:Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1078-0432
info:doi/10.1158/1078-0432.CCR-11-0070
info:pii/1078-0432.CCR-11-0070
info:scp/80455132309
info:pmid/21903773